Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00498927 · ClinicalTrials.gov registry record · Phase 2
Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT00498927: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00498927 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 47 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00498927, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well temozolomide works in treating patients with recurrent glioblastoma multiforme or other malignant glioma.
Primary Outcome
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Interventions
- GENETIC protein expression analysis
- DRUG temozolomide
- OTHER diagnostic laboratory biomarker analysis
- OTHER immunoenzyme technique
- GENETIC reverse transcriptase-polymerase chain reaction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2007-06 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
What the finished NCT00498927 record still lists
NCT00498927 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 5 interventions - of which protein expression analysis is the first listed.
NCT00498927 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00498927 about?
NCT00498927 is a clinical study titled "Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma". RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well temozolomide works in treating patients with recurrent glioblastoma...
What is the current status of trial NCT00498927?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2007-06. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00498927?
The interventions under investigation include: protein expression analysis (GENETIC), temozolomide (DRUG), diagnostic laboratory biomarker analysis (OTHER), immunoenzyme technique (OTHER), reverse transcriptase-polymerase chain reaction (GENETIC).
Who is sponsoring clinical trial NCT00498927?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00498927's enrollment target sits among peer trials
47 1283rd of 2000 higher than 715 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia